Clinical Trial Search

Phase 3 N=173 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Eyelash Hypotrichosis

Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 77.3; 17.6 Percentage of…

Allergan Results Jul 2013 2.3% serious AE View details

Phase 3 N=123 Safety and Efficacy of CJ-50300 in Healthy Volunteers

Smallpox

Primary: Cutaneous Take Reaction — 81; 41 participants

Seoul National University Hospital Results Jul 2013 0.0% serious AE View details

Phase 3 N=718 Efficacy of Nalmefene in Patients With Alcohol Dependence

Alcohol Dependence

Primary: Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) — -10.58; -12.30 days — p=0.012

H. Lundbeck A/S Results Jul 2013 3.1% serious AE View details

Phase 3 N=1,454 Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome

Dry Eye Syndrome

Primary: Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7 — 4.9; 4.8; -0.8; -0.7 Units on a scale

Alcon Research Results Jul 2013 0.1% serious AE View details

Phase 3 N=234 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Primary: Number of Participants With Splenectomy During 52-Week Treatment Period — 28; 14; 49; 143 Participants — p=<0.0001

Amgen Results Jul 2013 28.0% serious AE View details

Phase 3 N=310 A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

Crohn's Disease

Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of This Study CDP870-034 (up to 84 Months) — 94.2 percentage of subjects

UCB Pharma SA Results Jul 2013 44.5% serious AE View details

Phase 3 N=41 Open-Label Extension Study of Kuvan for Autism

Autistic Disorder

Primary: Clinical Global Impressions Scale — 3; 3 # participants much - very much improved — p=>.05

The Children's Health Council Results Jul 2013 0.0% serious AE View details

Phase 3 N=690 Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Open-Angle Glaucoma · Ocular Hypertension

Primary: Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3 — 21.1; 22.0; 23.2; 18.0 millimeters mercury (mm HG)

Alcon Research Results Jul 2013 3.0% serious AE View details

Phase 3 N=498 Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

Herpes Zoster · Shingles

Primary: Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody — 235.7; 208.2; 532.6; 457.1 Units/mL — p=<0.001

Merck Sharp & Dohme LLC Results Jul 2013 2.4% serious AE View details

Phase 3 N=216 Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

Heart Failure

Primary: Exercise Capacity, as Determined by Peak Oxygen Uptake — -0.07; -0.12 ml/min/kg

Duke University Results Jul 2013 19.0% serious AE View details

Phase 3 N=136 Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

Polycystic Ovarian Syndrome

Primary: Estradiol (E2) Levels on r-hCG Day — 1668.86; 1672.80 picogram/milliliter (pg/mL)

Merck KGaA, Darmstadt, Germany Results Jul 2013 4.6% serious AE View details

Phase 3 N=44 Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery

Coronary Artery Disease

Primary: Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood). — 632; 789 mL — p=0.0493

University of Saskatchewan Results Jul 2013 0.0% serious AE View details

Phase 3 N=101 A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

Human Immunodeficiency Virus Infections

Primary: Number of Subjects Needing to Switch Comparator Drugs (FPV/r or EFV) — 1; 2 participants

Georgetown University Results Jul 2013 4.0% serious AE View details

Phase 3 N=269 Clinical Evaluation of a 1-Piece Intraocular Lens

Cataract

Primary: Mean Percent Reduction in Cylinder — 32; 75; 76. percentage of reduction in cylinder — p=<0.0001

Abbott Medical Optics Results Jul 2013 2.2% serious AE View details

Phase 3 N=138 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access

End Stage Renal Disease

Primary: Cumulative Patency at 6 Months — 83.6 percentage of participants

W.L.Gore & Associates Results Jul 2013 53.6% serious AE View details